A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer | Zendy

Maria E. Cabanillas | Zendy; Marcia S. Brose | Zendy; Jaymes Holland | Zendy; Kimberly Ferguson | Zendy; Steven I. Sherman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer

Author(s) -

Maria E. Cabanillas,

Marcia S. Brose,

Jaymes Holland,

Kimberly Ferguson,

Steven I. Sherman

Publication year - 2014

Publication title -

thyroid

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.918

H-Index - 142

eISSN - 1557-9077

pISSN - 1050-7256

DOI - 10.1089/thy.2014.0125

Subject(s) - cabozantinib , medicine , tolerability , response evaluation criteria in solid tumors , medullary thyroid cancer , adverse effect , oncology , concomitant , cancer , thyroid cancer , tyrosine kinase inhibitor , phases of clinical research , surgery , clinical trial

Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib. Therefore, we evaluated cabozantinib in a cohort of heavily pretreated patients with metastatic DTC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research